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4. Abstract  
We have utilised modern methods of super-resolution fluorescent microscopy to spatially map 
fluorescently labelled ATP molecules in relaxed rabbit psoas skeletal muscles. For our imaging 
process, we have labelled ATP molecules with Rhodamine and Z-lines with Alexa488. Data from 
imaging these fluorophores have been collected using oblique angle fluorescent microscopy and 
further analysed to map super relaxed states (SRX) of myosin heads on the thick filament. Our 
experiments have concluded that most SRX of myosin heads were found in the C-zone of the 
thick filament, while other zones of thick filament had smaller populations of SRX. Further 
introduction of mavacamten (MAVA) to our imaging system has revealed an increase in SRX in 
both D and P zones, while the C zone population of SRX had remained constant. Further 
experiments must be conducted to establish a clear pattern and further proof our findings.  
 
5. Introduction 
A. Muscle composition 
i. Muscle Tissue 
Muscle is a type of soft tissue found in animals that enables organisms to move. Muscle has 
importance not only in gross body movement but also permits peristalsis and cardiac contraction. 
There are two primary types of muscle tissue: smooth and striated. The latter can be either 
skeletal or cardiac (see Figure 1). As its name suggests, cardiac muscle is found in the heart and 
is marked by its inability to fatigue despite pumping continuously over the organism's lifetime. In 
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humans, the amount of blood pumped by the heart is vast, estimated as ~80 Olympic-sized 
swimming pools in a lifetime (The Incredible Things We Know about Your Heart and Blood - BBC 
Future, n.d.). Skeletal muscle tissue is innervated, the voluntary muscle tissue that exhibits 
fatigue with high energy requirements. Both skeletal and cardiac tissues are organised into 
several bundles of myofibers. Myofibers, in turn, are divided into myofibrils which are then 
divided into a basic cellular unit called sarcomere (see Figure 2) (Mukund & Subramaniam, 2020). 
By contrast, smooth muscles found in veins and the gut walls are involuntary and activated by 
adrenergic and cholinergic receptors (J.R.Sellers, 2006). These tissues are much less organised, 




This figure shows all types of muscle tissue cardiac, skeletal, and smooth as an image of set muscles under the light 
microscope using different stains for contrast. A) An image of smooth muscle tissue under a light microscope with 
an example of an organ where this tissue type is present (gut). B) An image of cardiac muscle tissue under a light 
microscope with an example of an organ where this tissue type is present (heart). An image of skeletal muscle tissue 








This figure shows a labelled representation of different levels of striated muscle tissues organisation going down 
from the largest muscle fibres (myofibers) into myofibrils and further down to sarcomeres. This figure also depicts 
the observable distinctions of striated muscle that can be seen through a light microscope (i.e. Dark A bands and 
light I bands). Finally, this figure show structure of the sarcomere with division into different bands, including Z-lines 
in green with green straight lines representing thin filaments, M-lines in purple with purple lines representing thick 
filaments. (Samanthi 2017) 
 
 
ii. The sub-structure of striated muscle 
Striated muscle tissue is organised as many fused myocytes with joined cytoskeletons. 
Sarcomeres are the basic cell structures of striated muscles, which are continuous units of the 
component thick and thin filaments. Figure 2 shows that each sarcomere is defined at its ends by 
two Z-lines and an M-line in the middle. Z-lines are multiprotein structures that act as an anchor 
for the thin filament, which is joined to each Z-line extending towards the M-line. On the other 
hand, the thick filament is anchored and extends from the M-line in both directions towards the 
Z-line. The region where two filaments overlay in their extension is called an A band, while the 
regions where thick and thin filaments are present alone are called the H zone, and I band, 
respectively (see Figure 3). The reason why thick filament is anchored in M-line and thin filament 
is anchored in Z-lines is the protein composition of both Z and M lines and protein composition 
of both filaments.  
Alpha-actinin is a primary protein component of the Z-lines which forms the principal crosslinks 
between actin filaments of opposite polarity originating from adjoining sarcomeres. Alpha-
actinin is a rod-shaped protein of length ~35nm, which is an anti-parallel homodimer. The 
monomer of alpha-actinin comprises an NH2 terminal actin-binding domain composed of two 
calponin homology domains. The central part of alpha-actinin comprises four tandem sceptrin-
like repeats, each comprising a triple alpha-helix anti-parallel bundle. The actin-binding domain 
of each end of the dimer gives alpha-actinin the ability to crosslink actin filaments (Luther, 2009).  
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Not unlike Z-lines, M-lines are an anchoring point to the main component of the thick filament – 
myosin. M-lines are complex proteins that include titin, myomesin, obscurin and Obsl1, 
crosslinked through interacting Ig domains. In M-band, myosin filaments are crosslinked by a 
protein network composed of titin and proteins of the myomesin gene family, which comprises 
three MYOM genes. (Fukuzawa et al., 2008)(Katzemich et al., 2012). The roles of numerous 
proteins in both Z and M lines will not be discussed further but can be read about here (Knöll et 
al., 2002; Lange et al., 2020). Moreover, there are costameres, proteins associated with Z-lines 
that connect the intracellular environment of sarcomeres to the extracellular 
environment(Srivastava & Yu, 2006). These sub-sarcolemmal proteins are essential to maintain 
the regular work of contractile apparatus. Compromised costameres are thought to directly 
contribute to the development of several distinct myopathies(Ervasti, 2003). However, the 
primary focus should be on the aforementioned proteins – myosin and actin.   
 
Figure 3. 
This figure shows an in-depth dissection of a sarcomere. It includes both thick and thin filaments inside the 
sarcomere and multiple zones that define such arrangement. Thick filaments are represented by pink coloured lines 
anchored at M-line, which is represented by a yellow coloured line. Thin filaments are represented by light blue 
coloured lines and are anchored in Z-lines represented by darker blue coloured lines. (Russell and Edgewise 
Therapeutics 2021) 
 
iii. Thin filament structure and function 
Actin is a highly conserved and highly abundant protein in most eukaryotic cells. Actin in 
vertebrates can be expressed in three isoforms, including three α-isoforms of skeletal, cardiac, 
and smooth muscles and the β- and γ-isoforms expressed in both non-muscle and muscle cells 
(Dominguez & Holmes, 2011). Here we will be focusing on α-isoforms. G-Actin monomers (41,785 
Da) are globular proteins that are approximately 67 x 40 x 37 Å in size, has estimated isoelectric 
point pf 4.8 and net charge of -7 at pH 7 (Elzinga & Collins, 1975)(Elzinga & Collins, 1975)(see 
Figure 4A). Although the globular structure of G-Actin was established using scanning electron 
microscopy (SEM), further experiments using X-ray crystallography have shown that G-Actin 
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consists of two lobes separated by a cleft. The cleft is represented by the ATPase fold, a centre 
of enzymatic activity that binds ATP and Mg2+. ATP is then hydrolysed into ADP and inorganic 
phosphate (Pi). G-Actin can only function when either ATP or ADP molecule fills the cleft area, 
but the ATP molecules have higher affinity than ADP molecules (Graceffa & Dominguez, 
2003)(see Figure 4a). The polymerisation of G-Actin forms F-actin, which can be considered a 
single-stranded helix, rotating anticlockwise with a rotation of 166° around the helical axis and 
an axial translation of 27.5 Å(Von Der Ecken et al., 2015)(see Figure 4B). The polymerisation 
process requires ATP/ADP, proteins, and protein complexes to form F-Actin from G-Actin. Arp2/3 
is a complex of 220 kDa in size and has seven protein subunits. Arp2/3 initiates actin 
polymerisation by mimicking G-actin dimer. It attaches to the existing F-actin branch at 70°, 
allowing another G-actin monomer to attach and form a new F-actin branch (Suraneni et al., 
2015). Two proteins that are associated with G-actin polymerisation are thymosin and profilin. 
Thymosin is a small (5 kDa) protein that binds to the G-actin-ATP complex in a 1:1 ratio and 
impedes the incorporation of the monomers into the growing polymer(Goldschmidt-Clermont et 
al., 1992). Profilin is a larger (15 kDa) protein that binds to both G-actin-ATP and G-actin-ADP 
complexes in a 1:1 ratio instead of impeding the elongation of the filament facilitates the 
replacement of ADP by ATP(Carlsson et al., 1977). Formation of actin consists of “actin cycle” that 
adds G-actin-ATP complexes to filament’s barbed end where they “age” (changing ATP into ADP 
and Pi) while they are going towards the pointed end and simultaneous disassembly of F-actin-
ADP at the pointed end where ADP is refined back into ATP, this process of filament formation is 
known as treadmilling. Due to this process, actin filament remains in constant flux, assembling at 
the barbed end and disassembling at the pointed end. This process can be regulated, thus 
allowing for faster/slower assembly/disassembly to increase or decrease actin filament length, 







A) Shows labelled tertiary structure of G-actin with all subdomains, pointed and barbed ends and ATPase 
cleft(“File:G-Actin Subdomains.Png” n.d.). B) Shows a surface representation of repetition of 13 subunits of F-actin 
filament with pointed (-) end and barbed (+) ends. C) Shows the treadmilling process where polymerisation occurs 
at the barbed end while simultaneously depolymerisation occurs at the pointed end. ATP-actin is shown in yellow, 
while ADP actin is shown in grey. Orange circles represent molecules of profilin.  
 
The thin filament is associated with several proteins, including nebulin, polymers of tropomyosin 
and the troponin complex. During interaction with the S1 fragment of thick filament, actin 
filaments are capped at the pointed and barded ends by tropomodulin and CapZ, respectively. 
Titin is the largest know protein which in the human variant contains 34 451 amino acids with a 
molecular weight of approximately 3816 kDa. Titin extends throughout all sarcomere from M-
line to Z-discs. Titin consists of two different protein domains of 244 copies in total. The first 
domain is the fibronectin type III domain (132 copies). The second is the immunoglobulin domain 
(122 copies). The exact numbers of set domains may vary from one species to another(Labeit & 
Kolmerer, 1995). These domains can be further subdivided into two regions: the N-terminal I-
band region and the C-terminal A-band region. The I-band region's N-terminal acts as the 
molecule's elastic part and is composed of two immunoglobulin domains with the PEVK region 
in the middle. PEVK region is rich in proline, glutamate, valine and lysine(K. Wang et al., 1991).  
The C-terminal A-band region is thought to act as a protein ruler and is composed of altering 
fibronectin type III and immunoglobulin domains with super-repeat segments. These domains 
have been shown to align themselves with 43nm axial repeats of myosin filament to correlate 
with myosin heads(Bennett & Gautel, 1996) (see Figure 5). Titin is especially important for 
sarcomeres in the N-terminal I-band region, allowing for elasticity essential for the thin filament's 
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spring-like motions. Thin filament connects force-generating A-band to Z-lines while also 
providing a spring-like structure to make the contraction process reversible and mechanically 





A schematic representation of one half of the sarcomere where titin is shown in dark-filled circles. Titin is also 
represented in a more ordered state in A-band by dimmer filled grey circles. They represent the repetition of 
immunoglobulin and fibronectin II domains in the A-band.  All subdomains of titin are shown at the top of the 
diagram. Ig domains provide elasticity in I-band. Actin and myosin filaments are labelled appropriately. b) A 
structural representation of titis segment I65-I70. Grey structures represent 566 amino acid sequences divided into 
6 immunoglobulin modules. Cysteines locked in beta-strands B, F and G are labelled yellow, blue and red, 
respectively (Giganti et al., 2018). 
 
In striated muscles, actin filament is also associated with troponin and tropomyosin, which 
regulates the exposure of myosin-binding sites on thin filament, thus regulating muscle 
contractions. Tropomyosin is a long, coiled protein with a molecular weight of 65 kDa (about 
40nm in length). It binds to the thin filament covering seven adjacent G-actin monomers. 
Tropomyosin comprises two alpha-helix polypeptide subunits: alpha and beta tropomyosin. 
Troponin is a protein (80 kDa) that consists of three subunits Troponin C (18kDa), Troponin I 
(21kDa) and troponin T (31kDa). Each subunit has a function; Troponin C acts as a calcium-binding 
site which, if activated, deactivates troponin I through a consequent conformational change in 
troponin T, which acts as a bridge between troponin complex and tropomyosin. When troponin 
I is deactivated  (i.e. calcium ion is attached to troponin C), ATPase activity of actomyosin is 






The schematic architecture of actin filament. Tropomyosin twists around a thin filament with all three troponin 
subunits attached to actin filament and tropomyosin. Filled orange spheres represent actin. Intertwined brown and 
beige lines represent tropomyosin. Troponin I is represented by the green subunit, the red subunit represents 
troponin C, and the blue subunit represents troponin T. (Carrara 2017) 
 
iv. Thick filament structure and function 
Myosin is the main component of the thick filament. Myosin has 24 different classes with some 
structure variation; here, we will discuss Myosin II, which is expressed in animal striated 
muscles(Lynne M. Coluccio, 2008). Sarcomeric myosin is a hexameric motor protein composed 
of six subunits. Myosin has a molecular size of approximately 520 kDa. Myosin is composed of 
two heavy chains (MyHC), each with a molecular size of approximately 220 kDa. Due to their size, 
MyHC makes up the majority of the overall structure of myosin, two essential light chains (ELCs) 
which have a molecular size of 17 kDa and two regulatory light chains (RLCs), which have a 
molecular size of 20 kDa(Aguilar & Mitchell, 2010). Each MyHC comprises a globular motor head 
domain that bears ATPase activity and binds actin, a converter segment connecting the head 
domain to the lever arm that binds to ELC and RLC using isoleucine-glutamine (IQ) motifs and a 
“tail” that consists of the coiled-coil alpha-helix region. For further structural details, please see 
this review(“Myosin Subfragment-1: Structure and Function of a Molecular Motor,” 2007). 
Limited digestion by trypsin MyHC is fragmented into two parts: heavy meromyosin (HMM) and 
light meromyosin (LMM). LMM region interacts with adjacent LMM regions forming a cylindrical 
backbone (Lowey et al., 1993). HMM contains the head region, the converter segment, the lever 
arm, and the NH2-terminal portion of the alpha-helical rod domain (see Figure 7A). LMM contains 
the COOH-terminal half of the alpha-helical rod domain. 
Further digestion of HMM by papain leads to subfragments 1 and 2, S1 and S2, respectively. S1 
consists of a head domain, the converter segment, and the lever arm. S2 contains the NH2-
terminus of the alpha-helical rod domain(L. Wang et al., 2018)(see Figure 7B). The head region 
of S1 contains the ATP binding site and can be further subdivided into seven-stranded beta-
sheets surrounded by 17 alpha-helices. ATP binding is mainly regulated by the central (~50 kDa) 
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region of the globular head, which can be further divided into upper and lower 
subregions(Colegrave & Peckham, 2014) (see figure 7C). The cleft that forms between upper and 
lower sites contains the ATP binding site(Rayment & Holden, 1993). ATP binding to the ATP-
binding domain of S1 is coupled with the opening of the actin-binding cleft. The converter 
segment is connected to the head domain via relay helix, which is a long alpha-helix. The 
converter segment and relay helix play an essential role in fine-tuning ATP binding and hydrolysis. 




A structural representation of subsequently proteolyzed Myosin II. MyHC is shown to be broken down into LMM and 
HMM. HMM is then subsequently broken down into S1 and S2. The amplified structure of S1 is then shown with the 
motor domain represented in red, green, and blue. ELC and RLC are purple and yellow, respectively (Lynne M. 
Coluccio, 2008).B) A model representation of striated myosin S1 motor domain. Helices are shown in red, and key 
functional regions of the motor are ladled(Colegrave & Peckham, 2014). C) A structural representation of the folded 
form of myosin with two heads (blocked and free) with blocked head folding on the S2 coiled-coil domain of HMM. 




Myosin is the main but not the only component of the thick filament. Other essential proteins 
that compose the thick filament are myosin binding protein-C (MyBP-C), myosin binding protein-
H (MyBP-H), myomesin, M-protein and titin. MyBP-C has a molecular weight of 120-140 kDa, and 
MyBP-H has a molecular weight of ~52 kDa. They were first extracted from striated muscle in 
1973 as impurities in myosin preparations. Further studies have demonstrated that they are 
interaction partners of sarcomeric myosin. They are modular proteins consisting of 
immunoglobulin and fibronectin-III domains interspersed with unique sequences(L. Wang et al., 
2018). The extreme COOH-terminal immunoglobulin 8 – fibronectin-III – immunoglobulin 10 
13 
 
cassette of myosin binding protein-C and myosin binding protein-H supports binding to the LMM 
portion of myosin heavy chain(Gilbert et al., 1999). Furthermore, the NH2-terminus of myosin 
binding protein-C, specifically the Pro/Ala rich motif and M-motif flanking immunoglobulin 
domain C1 region, interact with the S2 fragment of myosin heavy chain(Flashman et al., 
2007)(see Figure 8). Myosin binding protein-C is much better defined than myosin binding 
protein-H. Further reading on myosin binding protein-H can be found here(Bähler et al., 1985), 
as it will not be discussed further in this thesis. Myomesin and M-protein have molecular weights 
of 185 kDa and 165 kDa, respectively. They both consist of immunoglobulin and fibronectin-III 
domains while being localised in the sarcomeric M-band. Myomesin interacts with the central 
LMM region of myosin heavy chains via the NH2-terminal My1 domain. Such interaction 
contributes to the assembly and incorporation of myosin into A-bands during 







A) A structural diagram of sarcomere with MyBP-C labelled in yellow. MyBP-C is confined to the C-zone (labelled in 
red) of the thick filament. D-zone is labelled in bright blue. P-zone is labelled in orange. The thick filament is shown 
in blue, while the thin filament is shown in greed. M line and Z lines are shown in grey. B) A structural diagram of a 
half thick filament with MyBP-C is attached to the thick filament and labelled yellow. The thick filament is blue, while 
the thin filament is labelled in green with pointed (-) and barbed (+) ends shown. C) A structural representation of 
the entire length of cMyBP-C. C1 and C2 domains are connected by the M-domain, containing an intrinsically 
disordered N-terminal region with four phosphorylatable serines and a less disordered C-terminal. C0 domain is 
specific to the cardiac isoform of MyBP-C. 
Globular heads of myosin molecules extend from the thick filament's core and interact cyclically 
with the thin filament in the process referred to as the cross-bridge cycle. The thick filament can 
be further subdivided into three zones C, D and P. The D-zone is situated on the z-line side of the 
thick filament, followed by the C-zone, and finally, the P-zone is directly adjacent to the M-line 
(see Figure 8A (Clark et al., 2002).  
 
 
B. Muscle contraction mechanics  
i. Sliding filament theory 
The Sliding filament theory was first proposed simultaneously by two different research teams 
Huxley & Niedergeke and Huxley & Hanson(A. F. Huxley & Niedergerke, 1954; H. E. Huxley & 
Hanson, 1954). Huxley & Niedergeke proposed a method using an interference microscope in 
which the reference beam does not traverse the specimen. Their setup was based on earlier 
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principles (here and later see references in the main text (A. F. Huxley & Niedergerke, 1954)), but 
further developments were incorporated to allow water-immersion objective for increased 
magnification and resolution. Due to the cylindrical shape of the fibre, gross refraction had to be 
brought to the average value for the fibre contents; this was done by adding serum albumin (a 
globular blood protein) to Ringer’s solution (isotonic buffer imitating body fluid salt 
concentration) that was used for the imaging. They have employed a constant cone of 
illumination throughout their experiments under which fibre was completely invisible with 
ordinary light, but the interference arrangement provided an excellent image of striations. The 
patter could be controlled to show (highlight) either A or I band as A had a higher reflective index. 
They have changed sarcomere length using three methods: passive stretch, isometric twitches, 
and isotonic contractions.  
Passive stretch employs stretching a stationary muscle. With this method, they saw an increase 
in length from 2 um to 4.2 um. According to their observations, the main change occurred in I-
band while A-band had a constant length. The isometric twitches method involved keeping the 
tendon ends stationary while simultaneously measuring the twitch with RCA 5734 transducer. 
They could not detect any change in band widths using this method. Lastly, isotonic contractions 
were applied where the muscle could contract freely. They saw various initial lengths up to 3.2 
um that would, similarly to their previous observations, only shorten in I-band while A band 
maintained constant width. With these experiments, Huxley and Niedergerke observed that: 
striations became very faint on shortening beyond a sarcoma length of about 1.8 um, the dense 
band narrowed to about half the sarcomere length, after which both bands narrowed in 
proportion, and at 1.8 um, a very narrow dense band was visible at the centre of the former A-
band, and on shortening to 1.7 um additional dense lines appeared midway between these lines 
(see Figure 9A&B). The hypothesis was proposed that the actin filaments fold into the A-band 
during contraction, and this folding continues after the I-band has been fully retracted. Unlike 
Huxley & Niedergeke, Huxley & Hanson (H. E. Huxley & Hanson, 1954) made their observations 
using high-resolution microscopy in phase-contrast illumination of the blended glycerol-
extracted rabbit psoas muscle. They have tested set myofibrils at different conditions. Firstly, 
they have allowed myofibrils to contract freely at room temperature (22° C) with 0.5 mM ATP, 
0.1 M KCl and 1 mM MgCl2. Secondly, they have allowed myofibrils to contract freely at room 
temperature but this time adding ATP at 5 uM as a series of steps, thus regulating the contraction 
degree. Thirdly, they allowed myofibrils to contract at low temperatures (about 2° C) with ATP 
but in the almost complete absence of Mg2+. Lastly, they have allowed myofibrils to contrast as 
in the first experiment, but myofibrils were held at both ends, so the shortening was controlled. 
During the first three experiments, they have observed identical changes of band pattern (see 
Figure 9C). They have also observed that the I band have shortened from 0.8 um to non-
existence, while the length of the A-band stayed constant at approximately 1.5 um. Furthermore, 
they have observed that although the A band did not change in length, it had changed in density. 
They observed that the H zone that was initially low in density has increased in density, first 
becoming indistinguishable from the rest of the A band, and then replaced (~85 % rest length) by 
the zone denser than the rest of the A band. The overall density of the A band decreases as 
myofibril diameter increases during the shortening. When I bands disappeared at about 65% rest 
length, contraction bands form at the lines of contact of adjacent A bands. During an isometric 
contraction, the lengths of both A and I bands do not change; however, a narrow dark zone 
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appears in the centre of the A band. Huxley & Hanson have arrived at several conclusions from 
the aforementioned experiments and other experiments exceeding the purpose of this thesis. 
First, the backbone of the muscle fibre is made up of actin filaments and stretches from Z lines 
to the H zone, where they are attached to an elastic component; they have named S-fragment. 
This component was thought to connect all sarcomeres via actin filaments stretching from both 
ends of Z lines. Second, myosin filaments are stretched from one end of A band, throughout the 
H zone, to the other end of the A band, and their length is unaltered by stretch or by contraction 
down to the point where the sarcomere length is equal to the length of the A band. Third, in the 
absence of ATP, myosin and actin filaments are interlocked in a permanent state of cross-linkage. 
Finally, they have proposed a possibility of driving force for contraction to be provided from the 










A passive stretch of muscle fibre. Positive contrast (A band dark). Scale is provided of x-axis in um. Almost all 
changes can be observed in lighter regions (I bands). B) Muscle fibres during short isotonic tetanus. Positive 
contras (A band dark). Again, A bands have a constant length while I bands (light) change. C) The same four 
sarcomeres of one myofibril photographed during contraction induced by ATP from rest length to 50 % rest 





The conclusion that was drawn from both papers presented above was the sliding filament theory 
which states that a decrease in the length of a sarcomere during contraction can be attributed to 
thin filament moving along the thick filament towards the M line, thus shortening H and I bands 
while A band remain at a constant length. Similarly, only I band and H zones increase in length 
during muscle relaxation, whereas A maintains its length and moves further away from the Z-
liens (see figure 10). Also, the fact that only A band does not shorten means that the only place 
of myosin-actin interactions is the A band which, in the absence of ATP, do not form any active 





A labelled structural representation of a sarcomere shows the change in all zones and bands during the contraction 
of a sarcomere. Blue filaments represent thin filaments. Pink filaments represent the thick filament. Zones and bands 









ii. Myosin heads cross-bridge cycle  
The myosin cross-bridge cycle is the process that involves myosin heads and actin filament 
interacting in A band to create the movement of the thin filament observed in sliding filament 
theory. Subfragment I of myosin heads consists of the motor domain and two light chain 
domains. The motor domain contains a nucleotide-binding site of the P-loop variety closely 
associated with switch-I and switch-II helices (see Figure 7A). ATP binding domain is located 
toward the end of a large cleft that separates two actin domain binding sites. ATP binding domain 
is also close to the P-loop and two switches that make myosin a part of a larger family of P-loop 
containing ATP and GTPases. Due to the ATP binding domain location, binding of ATP and 
subsequent release of ADP does not occur in the cleft directly but rather in a small pocket at the 
end of the cleft, where ATP molecule enters, Pi group first, followed by the main body of the ATP 
molecule thus blocking the exit of the hydrolyzed Pi molecule (M. A. Geeves et al., 2005)(Michael 
A. Geeves & Holmes, 2005). The nucleotide-binding site and actin-binding site communicate 
through the switch-I and switch-II helices, which move in response to the state of the nucleotide-
binding domain. Nucleotide-binding domain changes conformation depending on the present or 
absence of Pi in the active site (see figure 11 A). Other side of the motor domain (C-terminus) 
consists of a long alpha-helix stabilised by calmodulin or calmodulin-like light chains (the number 
of chains depends on the myosin isoform). This light chain binding domain is better known as the 
lever arm because it can swing through the angle of ~60° during the Lymn-Taylor contraction 
cycle (see Figure 11B). The myosin cross-bridge (Lymn-Taylor contraction cycle) cycle was first 
proposed by Lymn-Taylor in 1971 (Lymn & Taylor, 1971). During the Lymn-Taylor contraction 
cycle, the lever arm moves 5-20 nm in relation to the actin-binding site. (Wittinghofer & Geeves, 
2016).  
The Lymn-Taylor contraction cycle major events and conformation changes in the actin-myosin 
ATPase are described in Figure 11C. During Lymn-Taylor contraction, ATP acts as an inhibitor for 
actin-myosin interaction. By positioning itself in the cleft and forcing actin-binding regions on 
either side of the cleft apart, ATP reduces the affinity of myosin for actin by about 1000 fold. 
When ATP binds to ATP binding pocket, SW1 region closes first, thus opening large cleft region 
and releasing actin.  This is followed by the closure of the SW2 region. Closure of the SW2 region 
is linked to the recovery stroke in which the converter domain and lever are repositioned into 
the pre-power or working-stroke conformation.  The order of the events involving SW1 and SW2 
are precisely timed. SW1 closure and actin dissociation take ~ 1 ms. ATP hydrolysis occurs about 
10 times slower (~ 10 ms). The resulting complex is stable for ~ 20 s unless it encounters an actin-










A) A labelled structural representation of post-rigor myosin motor domain. This representation is shown from the 
pointed end of ancient at the point of attachment of S1 to actin. P-loop and adjacent helices are shown in yellow, 
while the N-terminus is shown in green. The upper 50 kDa domain of the motor domain is shown in red, while the 
lower 50 kDa domain is shown in grey. The disordered loop 1 that is comprised of the upper 50 kDa domain N-
terminus is marked by letters A and B. Disordered loop 2, which connects upper and lower 50 kDa domains, is marked 
by points C and D. Dark blue ribbon represents the C-terminal long helix which carries two calmodulin-like light 
chains and joins the thick filament. Relay helix is shown as a separate domain for clarity, but it is a part of the upper 
50 kDa domain. (Wittinghofer & Geeves, 2016). B) Structural representation of myosin power stroke, showing high-
resolution structures of myosin and actin in the pre-power stroke state, the rigour state and the post-rigor 
state(Dilson E. Rassier, 2013). C) A representation of ATP-driven actin-myosin mechanical cycle. The myosin cross-
bridge is shown to consist of three major components. 1. The central core of the myosin head (filled red circle) with 
the lower 50 kDa domain projecting up to make contact with a single actin monomer (filled grey circle). The myosin 
head remains a fixed reference point throughout the cycle. 2. The upper 50 kDa domain with SW1 is shown in yellow, 
which is drawn as two parts: the upper jaw of the major cleft that splits the actin-binding site and a ring with SW1 
projecting into the centre of the myosin head (both yellow). 3. A dark blue ring represents SW2 projecting to the 
centre while the converter domain and the lever arm stretches out of the ring (also dark blue). The nucleotide pocket 
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is represented by a red space inside two circles (yellow and dark blue). The nucleotide pocket has an entrance point 
represented by openings in two rings (blue and yellow). A-M at the top left represents the rigor actin-myosin 
complex, and the starting point with the upper 50 kDa domain cleft closed to allow both sides of the cleft to connect 
with actin. Both SW1 and SW2 circles are opened for ATP to enter the nucleotide pocket. The following numbers 
represent the numbers on the diagram indicating the step about to be described.  
1. ATP binds into the nucleotide pocket, and the yellow circle rotates to close SW1 ATP inside the pocket. During 
that process, the major cleft follows the movement of the SW1 circle, thus opening the major cleft, leading to 
dissociation from actin. 
2. The dark blue segment rotates to bring SW2 into contact with ATP. The motor domain restores its position before 
the power stroke. After both SW1 and SW2 circles are closed, ATP is hydrolysed to form a stable M-ADP-Pi complex.  
3. After ATP hydrolysis lower 50 kDa part of the cleft returns to its original position, thus rebinds to actin, the cleft 
closes, and both upper and lower 50kDa domains bind actin. The rebinding involves the rotation of the SW1 circle, 
thus triggering both Pi release and the rotation of the blue segment generating a force; a distortion of a converter 
domain represents the produced force. There is, however, no consensus on the ordering in which cleft closure, Pi 
release and powers stroke occur. The location of the elastic component within the cross-bridge is not defined.  
4. When/if enough force is generated in the previous step, the thin filament is moved 5-20 nm by the cross-bridge 
working stroke. This is shown as a relative displacement of the motor domain relative to the actin filament. Once 
the working stroke is finished, the blue segment shifts to allow ADP to escape the cleft in step 6. 
4a/5a. In a case where the force provided by the converter region is too small to move the thin filament, no sliding 
is taking place, and the further rotation of the blue SW2 ring is inhibited. The degree of set inhibition is defined by 
the load sensitivity of the myosin (~ 5-100 fold inhibition depending on the type of myosin)(Wittinghofer & Geeves, 




iii. Regulation of contraction  
There are two different regulatory systems. In actin-linked regulation, Ca2+ concentration 
regulates troponin, which regulates tropomyosin, which in turn regulates contraction by blocking 
myosin heads attachment sites on the actin filament. The three-state model was later proposed 
to state that calcium alone does not fully stimulate mechanical contraction (McKillop & Geeves, 
1993a). Similarly, a myosin-linked regulation system will block sites on the thick filament, 
preventing two filaments from attachment. Muscles of different species may have different 




iv. Thin filament regulation 
Muscle contractions are regulated by intracellular Ca2+ concentration. Calcium ions 
concentration affects the thin filament conformation, thus controlling the myosin heads 
attachment and muscle contractions. Parts of the thin filament that are important for contraction 
regulation are tropomyosin, troponin, and actin. They exist in thin filament in 1:1:7 
stoichiometry. Troponin can be further subdivided into troponin C, troponin I and troponin T 
(Ebashi et al., 1969). During the resting muscle state, intracellular calcium ion concentration is 
lower than uM level. This concentration is maintained by Ca2+ ATP driven pump that is located 
on the sarcoplasmic reticulum (SR) membrane, which pumps Ca2+ into the SR. With such low 
calcium concentration, most regulatory Ca2+ are dissociated from troponin C, thus driving thin 
filament into the inactive Ca2+ - off state. This state is defined by myosin heads disability to bind 
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to the actin filament. During muscle contraction, however, Ca2+ is released from the SR, allowing 
them to rebind to troponin C, which causes a conformational change in troponin and thus a shift 
in an azimuthal position of tropomyosin on the actin filament. The shift in tropomyosin allows 
actin-myosin interactions driving the thin filament into Ca2+ - on the state (Lehman et al., 1994).  
It has been shown (Moss et al., 1985) that removal of tropomyosin C from skinned muscle inhibits 
force production by preventing Ca2+ activation of the thin filament. Troponin C has two globular 
regions, COOH and NH2 terminals, connected by a long central helix. There are two possible Ca2+ 
binding sites on each region: helix-coil-helix E-F hands (see Figure 12 C). Under relaxed 
conditions, COOH-terminal sites (III-IV) have high (~107 M-1) Ca2+ affinity and sufficient Mg2+ 
affinity so that Mg2+ binds normally. COOH terminal sites are named structural sited due to their 
ability to enhance troponin C – troponin I interactions during Mg2+- Ca2+ binding and consequent 
binding of troponin C to the thin filament(Potter et al., 1995). The NH2 terminal site is a 
physiological Ca2+ trigger site; it lowers the affinity for Ca2+ and has a high selectivity for Ca2+ over 
Mg2+(Potter & Gergely, 1974). Further reading on tropomyosin C structure are available here 
(Sorenson et al., 1995)(van Eerd & Takahashi, 1976)(H. L. Sweeney et al., 1990). Tropomyosin 
interaction with actin is influenced by troponin and myosin that significantly increase 
tropomyosin binding to actin. These interactions can be found in 14 quasi-equivalent repeats of 
consequent regions of charged and uncharged amino acid side chains of tropomyosin(McLachlan 
& Stewart, 1976). These electrostatic interactions of tropomyosin and actin can be divided into 
two different states(Phillips et al., 1986). Images of tropomyosin on F-actin taken with X-ray 
support the electrostatic binding on the periphery of the actin filament(Lorenz et al., 1995). 
Further reading on different isoforms of tropomyosin and their properties are available here 
(Mak & Smillie, 1981)(Landis et al., 1997)(Hitchcock-DeGregori & An, 1996)(Chandy et al., 
1999)(Swenson & Stellwagen, 1989). Three-state (blocked, closed, and open) dynamic steric 
model (see Figure 12 D, E&F) was proposed for tropomyosin states during actin-myosin 
interactions(McKillop & Geeves, 1993b). Multiple studies (Vibert et al., 1997)(Lehman et al., 
1994, 1995) on the negatively stained thin filament and stained frog muscle have shown that 
tropomyosin in the absence of Ca2+ occupies the position that blocks most myosin-binding sites 
(blocked) on the actin filament. After Ca2+ attaches to troponin, tropomyosin moves ~25° around 
the surface (closed) of thin filament from its previous position exposing several more myosin-
binding sites(Vibert et al., 1997; C. Xu et al., 1999). Troponin was moved further 10° (open) upon 
the addition of S1 but in a total absence of MgATP. Further biochemical evidence supporting the 
three states theory had shown that open state was only present at rigor but required Ca2+ and 
strong binding of myosin heads (Vibert et al., 1997). Further reading on blocked, opened and 
closed states are available here (Poole et al., 2006)(McKillop & Geeves, 1993a)(Pirani et al., 2005). 
Another very recent paper has shown the conformational change of troponin due to Ca2+ binding 
by utilising new methods of cryoEM and image analysis (Yamada et al., 2020). In this study, they 
have shown the entire length of actin filament with detailed structures of troponin core, the 
entire length of tropomyosin with the head-tail junction, the N-terminus extension of troponin T 
and the C-terminus extensions of troponin I below and above the troponin core, respectively. 
Troponin core structure has been shown before(Takeda et al., 2003) and is coherent with results 
from this study. The inhibitory role of the C-terminus of the troponin I chain, which is located 
downstream of Gly 137, has been well characterised by biochemical studies (M. A. Geeves et al., 














A) A 3D model of an actin filament viewed from the pointed end shows a conformational change in troponin and 
tropomyosin that occurred before, and after Ca2+ binding to troponin C. Troponin C N-terminus is labelled in greed 
while C-terminus is labelled in yellow. Tropomyosin is represented in bright blue. Troponin I switch is represented 
in purple. Actin is represented in pale yellow. Troponin I and T arms are represented by red and blue helices, 
respectively (Yamada, Namba, and Fujii 2020).  
B) A schematic diagram of a change in troponin and tropomyosin during the Ca2+ binding and consequent effects 
that unlock myosin heads binding sites. Troponin I C-region is represented in dark purple. Tropomyosin I is 
represented in light blue, while actin is represented in pale yellow. Troponin core is represented in green, red and 
blue. Myosin binding sites are represented in grey (closed) and pink (opened) (Yamada et al., 2020).  
C) Left: a structural representation of troponin C crystal structure with Ca2+ bound only to NH2 terminal. Solid circles 
represent Ca2+. Letters represent 8 helices of NH2 terminal showing their orientation. Right: a structural 
representation of troponin C crystal structure with Ca2+ bound to NH2 and COOH terminals. In this model, helices are 
oriented more parallel to each other compared to the previous model (Yamada, Namba, and Fujii 2020). D) A 
representation of the actin-troponin complex in a blocked position. Here and further, tropomyosin is represented in 
see-through green. Actin is represented in pale green. Bright colours (green, red, blue and purple) represent 
potential myosin-binding sites on the actin filament. Actin residues are coloured: 1-4,24-28 green, 144-148,340-346 
blue, 332-336 purple and 93-96 red. E) A representation of the actin-troponin complex in the closed position. F) A 




v. Thick filament regulation  
1. Super Relaxed State & Disordered Relaxed State of myosin heads in striated muscle 
Super Relaxed state (SRX) and Disordered Relaxed state (DRX) can be defined as states of myosin 
heads that have a slower nucleotide turnover than active myosin head turnover rate (~ 1-4 s). 
DRX was shown to have an ATP turnover rate of ~20 s, while SRX was shown to have an ATP 
turnover rate of ~230+-24 s(Hooijman et al., 2011);(McNamara et al., 2014).  The structure 
proposed to associate with SRX and DRX is called interactive head motif (IHM). Closed (IHM) state 
of myosin heads was shown to be a favourable state of myosin heads which was observed in both 
purified myosin(Burgess et al., 2007; Hyun et al., 2008; Jung et al., 2011; Wendt et al., 1999, 2001) 
and in isolated thick filaments from striated muscles(Woodhead et al., 2005; Zoghbi et al., 2008) 
(see Figure 13 A & B). The initial discovery of SRX was made in rabbit skeletal muscle, but shortly 
after, it was shown to exist in rabbit cardiac, tarantula exoskeletal, mouse skeletal and human 
cardiac fibres(Hooijman et al., 2011)(Alamo et al., 2016; Cooke, 2011; Wilson et al., 
2014)(Anderson et al., 2018). Sarcomeric proteins like myosin binding protein-C (MyBP-C) have 
been shown to control over SRX and DRX states of myosin heads(McNamara et al., 2019). In IHM, 
the interaction between myosin heads and myosin-binding regions of the actin filament is 
inhibited by interactions of myosin heads with each other and their fold back on the myosin tails 
(Irving & Craig, 2019). Further proof has been shown to underline the relation between SRX and 
IHM (Zhao et al., 2008)(Wilson et al., 2014). SRX and DRX coexist in a constant state of dynamic 
equilibrium. Such an equilibrium exists to create a more energy-favourable system in which less 
energy is used due to a larger part of myosin heads being in SRX rather than DRX. If all heads 
were to be in DRX, metabolic intake of an additional ~1000 Cal per day (~50% increase in 
metabolic rate) would be needed to compensate for energy requirements(Cooke, 2011). In 
skeletal muscle, SRX was shown to convert to DRX in times of extreme stress, which would make 
sense due to the instant contraction force that is required from skeletal muscles (Linari et al., 
2015). Interestingly, several pharmaceutical companies are currently pursuing pharmaceutical 
agents that would initiate a decrease in SRX in favour of DRX to produce a drug for treating 
obesity and type two diabetes by increasing a patient's metabolic rate (Nogara et al., 2016).  
Studies performed on both skeletal and cardiac fibres revealed a difference in SRX states in 
different started muscles. During the addition of excess ADP to the muscle tissue, the proportion 
of SRX was fully turned into an active state in skeletal muscles while cardiac muscles retained 
some SRX(Hooijman et al., 2011). Several mechanisms that would explain the sudden change 
from SRX to the active state were proposed for skeletal muscles. First, an unproven but 
straightforward explanation is that a myosin head brought out of SRX disrupts SRX in adjacent 
myosin heads, thus bringing them all into the active state(Moss & Fitzsimons, 2010).  Second, a 
theory proposes that since myosin MyHC (in tarantula thick filament) has two heads of which one 
is strongly bound to the core of the thick filament and has no affiliations with actin and the second 
one which can extend towards thin filament and interact with actin, it is possible that 
configuration of vertebrate skeletal muscle also has a similar structural configuration which 
allows actin-binding head to cooperatively activate thick filament (Brito et al., 2011)(Sulbarán et 
al., 2013). The cardiac muscle “not-complete” decrease in SRX during ADP addition is associated 
with the difference in the physiological functions of set muscle tissues(McNamara et al., 2014). 
The ultrastructures of thick filament have been solved (Crowther et al., 1985) and improved by 
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using cryo-EM and improved image processing (Roger Craig & Woodhead, 2006; Woodhead et 
al., 2005). The structural interactions in adjacent myosin heads have been shown in tarantula 




A) A structural representation of myosin head subfragment 1 in the pre-stroke state. The ELC is shown in brown, 
while RLC is shown in green. B) A structural representation of open and closed IHM states of myosin head HMM. The 
motor domains are coloured black (blocked head) and grey (free head). The ELCs are shown in brown, while RCLs 
are shown in green. S2 helix is shown in pale blue. R663H and R403Q mutations associated with hypertrophic 






a. Myosin Binding Protein-C 
Myosin binding protein-C is a myosin filament associated protein that modulates cross-bridge 
formation and kinetics (Koretz, 1979; McClellan et al., 2001). There are three isoforms of MyBP-
C: slow skeletal, fast skeletal, and cardiac. MyBP-C can only be found in the C-zone of the thick 
filament, and it is regularly patterned in 7-9 transverse parallel stripes approximately 43 nm 
apart. MyBP-C can be described as polymer protein approximately 40 nm in length and 3 nm in 
width with a molecular weight of about 140 kDa. MyBP-C has 10 domains C1-C10, the actual 
binding motif is situated between C1 and C2 subdomains. In the cardiac isoform of MyBP-C, there 
is also an immunoglobulin domain in the C0 subdomain and 4 serine residues in the M-domain 
(Yasuda et al., 1995) (Gautel et al., 1995).  With C-terminus, myosin binding, protein-C binds to 
the thick filament, while with its N-terminus, it can interact with both the actin filament and 
myosin heads(Moos et al., 1978; Shaffer et al., 2009). The aforementioned serine residues can 
be phosphorylated by several kinases (Barefield & Sadayappan, 2010). Experiments have shown 
that mice trabeculae treated with protein kinase A (PKA) had demonstrated increased 
contractility. PKA mimics beta-adrenergic activation, which enables the release of myosin heads 
from the thick filament, thus enabling them to move closer to the thin filament(Colson et al., 
2008, 2010). Further reading on mice experiments (Colson et al., 2007, 2008, 2012). A more 
recent study (McNamara et al., 2019) (also on mice) aimed to determine the mechanism by which 
cardiac myosin binding protein-C phosphorylation increases contractile kinetics.  This study 
tested the hypothesis that phosphorylated cardiac myosin binding protein-C increases the 
number of active myosin heads by releasing them from SRX into a more active state. In this study, 
mice with different (alanine or aspartic acid) substitutions for three main phosphorylatable 
serines (273,282 and 302) of cMyBP-C were used to establish the relation between cMyBP-C and 
SRX. Their experiments had shown that phosphomimetic cMyBP-C destabilized SRX, while 
phosphor-ablated cMyBP-C was stabilising SRX. Serine 282 sites were found to play a critical role 
in SRX regulation. Experiments with PKA were also conducted in this study on wild type mice 
samples. They have shown a reduction in SRX, thus confirming the results from previous studies. 
They have also added PKA to non-phosphorylatable cMyBP-C samples where there was no 
detectable effect. During other experiments, they added recombinant myosin S2 to their 
samples, where they saw a significant decrease in the SRX population, thus increasing force 
generation and rate of tension redevelopment in skinned fibres. Interaction between cardiac 
isoform of myosin binding protein-C and RLC was proposed in 1985 (Margossian, 1985). It was 
suggested that such an interaction might be via the cardiac-specific domain C0 of cardiac myosin 
binding protein-C (Ratti et al., 2011). This suggestion is supported by the results (Harris et al., 
2004; Herron et al., 2006; Kunst et al., 2000) obtained from experiments with short, N-terminus 
MyBP-C fragment as it contains C0 domain. It must also be added that genetic mutations in the 
MYBPC3 gene that encodes for myosin bind protein-C constitute a significant cause of 
hypertrophic cardiomyopathy (HCM) comprising ~ 40 % of all known mutations (Van Dijk et al., 
2009). Together with mutations in other major thick filament binding proteins that include ELC, 





b. Regulatory light chain and phosphorylation  
Regulatory light chain (RLC) is a part of myosin HMM, essential in converting chemical energy 
into mechanical work. It was shown that by removing light chains, the sliding velocity of actin 
filament in motility assays has decreased by 10 without affecting ATPase activity (Lowey et al., 
1993).  In human cardiac muscle, RLC is phosphorylated at Ser-15 by the Ca2+/calmodulin-
dependent myosin light chain kinase (MLCK) (Scruggs et al., 2010). The phosphate group that 
binds to RLC has a negative charge, thus repelling RLC with myosin head from thick filament core 
(H. Lee Sweeney et al., 1994)(Levine et al., 1996). The repulsion was shown to reduce the 
proportion of myosin heads in SRX through the electron micrographs and X-ray diffraction studies 
of the tarantula thick filament. This study had shown MLCK treatment disorders myosin heads in 
the relaxed state (R. Craig et al., 1987; Padrón et al., 1991). Further studies in tarantula have 
shown that phosphorylated RLC reduces the proportion of SRX via disorder in the helical 
structure of the thick filament (Alamo et al., 2008). Studies in vertebrate cardiac muscle treated 
with MLCK have shown an increase in density of cross-bridges near the thick filament, which 
indicated a high level of thick filament disorganisation (Colson et al., 2010). The treatment of RLC 
with MLCK increases resting and maximum force, the rate of force development and Ca2+ 
sensitivity in cardiac trabeculae, thus allowing phosphorylated RLC to shift myosin heads from 
SRX into DRX. The increase in Ca2+ would precipitate the changes in actin filament described 
before, which, together with changes to RCL, would result in increased resting and active forces 
(McNamara et al., 2014). Studies in rat trabeculae have shown that MLCK phosphorylated 
recombinant RCL have increased maximum power output and shortening velocity compared to 
while type (Toepfer et al., 2013). Rats in which RLC was either dephosphorylated or non-
phosphorylatable have experienced a 4-fold decrease in isometric force and reduced maximum 
power compared to phosphorylated and wild type RLC mice (Scruggs et al., 2009; Toepfer et al., 
2013). The transgenic mice have also experienced a presence of systolic impairment without any 
change in end-diastolic volume, thus leading to the conclusion that RLC dephosphorylation may 
reverse myosin heads from DRX back into SRX, resulting in reduced force production (Stewart et 
al., 2010b)(Naber et al., 2011). Studies of human heart failures associated with HCM have been 
shown to relate to RLC coding sequence mutations and a general increase in RLC phosphorylation 




C. Hypertrophic Cardiomyopathy  
i. General Information and significance  
HCM is the most common genetic heart condition with a mutational prevalence of 1 in 500 
(Hypertrophic Cardiomyopathy (HCM) | American Heart Association, n.d.; Hypertrophic 
Cardiomyopathy (HCM) | BHF, n.d.). Physiological manifestations of HCM may vary considerably, 
and pathophysiology is not always closely linked to outcome (Marian & Braunwald, 2017). 
Overall, HCM results in a thickening of the left ventricular wall up to  >=13 mm in adults (Maron 
et al., 1995). HCM can be defined as an archetypical single gene disorder with an autosomal 
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dominant inheritance pattern (Greaves et al., 1987). In other words, a single mutation is usually 
a cause of HCM. The large variability in the phenotype of HCM is mainly due to the other genetic 
and non-generic influences (Marian & Braunwald, 2017). The link with the X-linked model (sex-
related) is documented but rare (Hartmannova et al., 2013)(Branzi et al., 1985). Good examples 
of mutations that have been shown to link with HCM are Atg403Glu mutation in the MYH7 gene, 
which encodes a beta-myosin heavy chain and mutations in MYBPC3 that codes for myosin 
binding protein C (Geisterfer-Lowrance et al., 1990). These two mutations are the most common 
mutation causes for HCM and are responsible for about 50 % of HCM cases(Millat et al., 
2010)(Richard et al., 2003). HCM is a genetically related disease; thus, family history of HCM or 
genetic testing may reveal the presence of this disease.   Apart from genetic testing, an increase 
in left ventricle wall thickness to greater than 13 mm will cause HCM diagnosis if there is no other 
cardiac or systemic disease capable of explaining this thickening. HCM diagnosis in most often 
established with non-invasive cardiac imaging (e.g. echocardiography, cardiac magnetic 
resonance imaging). Physical manifestations of HCM are highly variable. Some of them may 
manifest into arrhythmias (atrial fibrillation and malignant ventricular arrhythmias) or may be 
asymptomatic all together (Cirino & Ho, 1993). Full list of symptoms includes exertional dyspnea, 
fatigue, palpitations, light-headedness, syncope, atypical chest pain and sudden cardiac death 
(SCD). The degree of severity of symptoms highly depends on the degree of left ventricle 
hypertrophy (LVH) and severity of left ventricular outflow track obstruction (LVOTO). Large 
proportion of young patients with HCM remain asymptomatic or minimally symptomatic 
throughout life. The most devastating complication that may occur with HCM patients is SCD. 
SCD triggers remain poorly understood (Teekakirikul et al., 2019).  
ii. HCM association with mutations in the components of the thick filament  
MYBPC3 gene encompasses more than 21 kbp and comprises 35 exons, including 34 coding (see 
Figure 14)(Carrier et al., 1997). MYBPC1-3 codes the three isoforms of myosin binding protein-C 
for slow skeletal, fast skeletal, and cardiac, respectively. At this moment, more than 350 
individual mutations in MYPBC3 were identified in patients with inherited HCM. This number 
represents 40-50 % of all HCM mutations, making it the most frequently mutated gene in HCM 
(Behrens-Gawlik et al., 2014; Schlossarek et al., 2011). More than 60 % of MYBPC3 are truncating 
mutations. They include nonsense mutations, insertion, deletion, splicing and branch point 
mutations. These mutations lead to COOH-terminally truncated cMYBP-C, which lacks the major 
myosin and/or titin binding sites (Behrens-Gawlik et al., 2014). MYBPC3 associated HCM 
mutations are primarily heterozygous, thus resulting in late disease onset (Carrier et al., 2015). 
Founder mutations have been identified in multiple studies (Adalsteinsdottir et al., 2014; Calore 
et al., 2015; Christiaans et al., 2010; Jääskeläinen et al., 2004; Kubo et al., 2005; Niimura et al., 
1998) and can all be underlined by truncating mutations that result in shorter cMyBP-C which 
lacks phosphorylation M motif and/or major binding domain to other sarcomeric proteins. For a 






A schematic representation of myosin binding protein-C coding gene MYBPC3 with mRNA, protein structure, 
interactome (interaction partners) and PTMs (sites of posttranslational modifications. Cardiac isoform-specific 
regions are labelled in yellow. Different posttranslational modifications are labelled in different colours with legend 
provided (Carrier et al., 2015). 
 
Mutations in RLC and ELC coding genes can also cause HCM. In early research, the analysis of RLC 
gene MYL2 and ELC gene Myl3 for 186 unrelated individuals with HCM had precipitated two 
mutations in MYL2 that may associate with HCM. These missense mutations we very different. 
One was associated with early stages with no clinical manifestation, while the other was 
associated with early onset of clinical manifestation and premature SCD. The conclusion was 
drawn that mutations in MLC are very rarely (about 1 %) the cause of HCM (Kabaeva et al., 2002). 
A more recent study shows that R58Q mutation in RLC is associated with HCM. They show that 
R56Q mutation promotes an OFF state of the tick filament by increasing the number of SRX states 
of myosin heads, thus reducing ATP turnover rate and slowing interaction between actin and 
myosin filaments in A-band. They also show that the phosphorylation of R58Q mutated RCL to 
normal physiological levels restores the thick filament's regulatory state and increases calcium 
sensitivity. They concluded that missense mutation in R58Q is associated with HCM and that this 
signalling pathway offers a promising target for pharmaceutical development (Kampourakis et 
al., 2018). Further reviews of different musicians in RLC causing HCM are available here (Huang 
& Szczesna-Cordary, 2015). Mutations in titin coding genes like TNNT2, TNNI3 and TPM1 are a 
less common cause of HCM. They cause less than 10 % of cases (Erdmann et al., 2003; Kimura et 
al., 1997; Richard et al., 2003; Thierfelder et al., 1994). Mutations in other coding genes like 
cardiac alpha-actin (ACTC1), cysteine and glycine-rich protein 3 (CSRP3) are a cause of HCM, 
although these are even less common (Geier et al., 2008; Mogensen et al., 1999). 
 
D. Pharmacology 
i. Mavacamten and omecamtiv mecarbil 
Mavacampten (MAVA), formerly known as MYK-461, is a selective allosteric inhibitor of cardiac 
myosin ATPase, which causes a decrease in contractile activity of the left ventricle in both healthy 
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and HCM patients. Currently, this drug is in phase 3 clinical trials. MAVA acts directly by 
interacting with human beta-cardiac myosin and normalizing its power output. MAVA was 
identified during the actin-activated myosin ATPase inhibitors trial as it could lengthen the total 
cycle time of the ATPase cycle by pushing myosin heads into SRX state. MAVA was shown to drive 
myosin heads into the state of SRX by adding it to purified human beta-cardiac myosin. In this 
experiment, 10 uM MAVA in the presents of 25-hep HMM at both 25 mM and 100 mM potassium 
acetate was shown to be approaching 100 % SRX. Although it is known that MAVA inhibits the 
actin-myosin cross-bridge formation, the precise mechanism of inhibitions is unknown (Anderson 
et al., 2018). Further figures should be provided to indicate the success that MAVA achieved 
during the last phase of its pharmaceutical trials. Fifty-nine participants with the mean age of 54 
years and 58 % women were subjected to 200 ng/ml,500 ng/ml and 0 ng/ml of MAVA. Serious 
adverse events in patients occurred in 10 % of >0 ng/ml participants and 21 % of participants on 
placebo. Five MAVA(>0ng/ml) participants were observed to have a reversible reduction in LVEF 
by <=45 %(Ho et al., 2020).  
Omecamtiv Mecarbil (OM), formerly known as CK-1827452, is a selective cardiac myosin 
activator. OM specifically binds to the S1 domain of the cardiac myosin head without any specific 
effect on other types of muscle tissue (i.e. skeletal and smooth). Unlike MAVA, OM has a clear 
mechanism of action. OM has a binding site in a narrow cleft between the N-terminus 25-K 
domain and the lower portion of the 50 kDa domain. OMs attach to serine 148, which is ~6.5 nm 
from the actin-binding site of the myosin head and ~3 nm from the ATP binding site. The 
conformational change produced by OM attachment results in increased speed of ATP hydrolysis 
by myosin heads that consequently increase the speed of Pi release, thus accelerating the 
transition from weakly bound to strongly bound force-producing state (Kaplinsky & Mallarkey, 
2018). Essentially OM in opposition to MAVA drives myosin heads from SRX into DRX and DRX 




E. Other recent sarcomeric imaging studies 
A recent study (Pandzic et al., 2020) showed a new method of observing and analysing data 
recorded by treating cardiac muscle with blebbistatin and comparing pre-blebbistatin with post-
blebbistatin treated muscle. Blebbistain is a myosin inhibitor most specific for myosin II. In their 
experiment, two types of ATP-Alexa-647 attachments were measured. First was free (unbound) 
ATP molecules; these attachments could be characterised as ATP molecules that are not bound 
to the myosin heads but instead exist free in sarcomeric space. The second type was bound ATP 
molecules; these are ATP molecules bound to myosin heads. By measuring, normalising, and 
plotting the binding of these two types of ATP molecules, they have shown that the addition of 
blebbistatin increased the binding times of bound ATP molecules and decreased the number of 
unbound ATP molecules. They have concluded that blebbistatin pushed myosin heads into the 
SRX, thus increasing the attachment time for bound ATP and reducing the number of free ATP 
molecules as more of them were stuck in SRX. Stochastic Optical Reconstruction Microscopy 
(STORM) is one of the super-resolution (SR) fluorescent microscopy technics that are used to 
increase the diffraction-limited resolution(Heilemann et al., 2008; Rust et al., 2006). Other SR 
techniques include structured illumination microscopy (SIM) (Gustafsson, 2000), stimulated 
emission microscopy (STED) (Hell & Wichmann, 1994) and photo-activated localization 
(fluorescent) ((f)PALM) (Betzig et al., 2006; Hess et al., 2006). STORM resolution is advantageous 
to other SR techniques as it uses organic dyes and has a resolution of ~20 nm. STORM utilises 
optically switchable fluorophores, which are switched between fluorescent and non-fluorescent 
states in each frame. With a large number (typically 5, 000 – 40, 000 frames) of frames taken 
localization algorithm determined the centre positions of each fluorescent event at a nanometre 
scale. Finally, with an overwhelming number of fluorophore centres analysed, the final images 
are reconstructed with resolution improved by 10 times (J. Xu et al., 2017). Multiple reviews have 
been written for general principles of STORM and detailed labelling of photo-switchable 
fluorophores (Bates et al., 2013a, 2013b; Endesfelder & Heilemann, 2014; Van De Linde et al., 
2011).  
Another recent study (Nelson et al., 2020) was conducted to investigate the spatial arrangement 
of ATP molecules in relaxed striated muscle and the effects of MAVA on myosin heads in set 
muscles. In this study, STORM was used to determine the spatial arrangement of BODIPY-ATP 
attaching to each zone of the thick filament with both frequency and duration of ATP 
attachments. Data analysis that followed produced two distinctive lifetimes of ATP molecules 
fitted to two exponentials. These two exponentials are believed to represent DRX and SRX states 
of relaxed myosin heads. ATP molecules were separated into C, D, and P zones with both position 
and durations. The zones were determined using anitimyomesin-labelled M lines. After 
separating events into different zones, the amount of SRX myosin heads were determined for 
each zone using the durations of ATP attachments. Experiments were repeated with presents of 
MAVA (MAVA+) and without MAVA present (MAVA-). The results indicate that in MAVA- a 
condition, the largest portion of SRX states were localised in the C zone, while the D and P zones 
had mainly DRX. Upon the addition of MAVA, all zones appear to have the same amount of SRX 






A) Top image shows fluorescently illuminated M-lines and fluorescently labelled ATP molecules shown in green. 
Bottom images Bottom panel shows the top image that was colour and drift corrected using subpixel localisation. 
Myomesin-labelled M-lines are shown as black dots. Fluorescently labelled ATP molecules are still shown in green. 
Green stars represent ATP attachments observed in the top panel. B) A graph representing time versus distance 
from the M-line of fATP binding events. C) A root mean-square deviation heatmap that compares predicted SRX-
containing zones of variable width to experimental data. D) A survival plot representing lifetimes of events D, C and 
P zones acquired in experiments without MAVA. The dotted red line represents a simulated zone with all myosin 
heads in SRX, while the green one represents a simulated zone with all myosin heads in DRX. The bar chart at the 
top-right corner of the graph represents the proportion of SRX (shaded-SRX, non-shaded DRX) in each zone. E) Same 






F. Aim of this thesis 
This thesis will describe our way of preparing, imaging, and analysing spatial arrangement of 
Rhodamine-labelled ATP molecules with anti-alpha-actinin labelled Z-lines for the goal of 
determining the SRX arrangement in C, D and P zones of the thick filament, as well as using 
MAVA+ experiments for comparison with MAVA- conditions and further proof of MAVA 
effectiveness in inhibition of myosin heads. Much like the two studies described above, we aim 
to establish a methodology for single-molecule muscle analysis's experimental and analytical 
parts. Although at this stage of this thesis will be focusing exclusively on skeletal muscles, we 
would like to hope that in the future, it will be possible to expand our attempts into healthy 
cardiac muscles and cardiac muscles from HCM affected patients.  
 
7. Materials and Methods  
A. Buffers and Reagents  
All buffers were diluted using purified water at an 18.2 mΩ/cm resistance from a Synergy 
ultrapure water (Type 1) system at room temperature. Sodium-azide was added to long-term 
storage buffers for microorganism growth control.  
 
Fibre preparation buffer: 
6 mM Imidazole, 8 mM Mg-acetate, 70 mM Propionate pH 7.0, 5 mM EGTA, 7 mM ATP, 1 mM 
Na-azide 
 
Fibre skinning buffer: 
6 mM Imidazole, 8 mM Mg-acetate,70 mM Propionate pH 7.0, 5 mM EGTA, 7 mM ATP, 1 mM Na-
azide, 0,5 % HO(C2H4O)20C16H33 
 
Fibre storage buffer: 
6 mM Imidazole, 8 mM Mg-acetate, 70 mM Propionate pH 7.0, 5 mM EGTA, 7 mM ATP, 1 mM 
Na-azide, 50 % Glycerol 
 
Fibre buffers contained Imidazole Mg-acetate Propionate and ATP to imitate conditions in 
relaxed conditions living muscle tissue. EGTA was added to deprive tissues of any Ca2+ and thus 
prevent contractions. HO(C2H4O)20C16H33 was added for chemical skinning. Glycerol was added to 
prevent water in muscle tissues from freezing while allowing for storage at -20 °C. 
 
Wash Buffer: 
6 mM Mg Acetate, 10 mM EGTA, 54 mM Na Acetate, 18 mM Na2SO4, 10 mM MOPS, 1 mM DTT* 




Wash Buffer (relaxed): 
6 mM Mg acetate, 10 mM EGTA, 54 mM Na Acetate, 18 mM Na2SO4, 10 mM MOPS, 5 mM ATP**, 
1 mM DTT* 
*Add on the day of the experiment  
** Added on the day and varied depending on experimental requirements 
 
 
250uM dATP wash buffer: 
10 uM dATP, 1 mg/ml BSA, 50 nM PEP, 1 ul PK, 6 mM Mg Acetate, 10 mM EGTA, 54 mM Na 
Acetate, 18 mM Na2SO4, 10 mM MOPS, 1 mM DTT* 
*Add on the day of experiment  
 
 
50nM RdATP imaging buffer: 
50 nM RdATP, 1 mg/ml BSA, 50 nM PEP, 1 ul PK, 6 mM Mg Acetate, 10 mM EGTA, 54 mM Na 
Acetate, 18 mM Na2SO4, 10 mM MOPS, 1 mM DTT* 
*Add on the day of experiment  
 
Wash and imaging buffers contained Mg Acetate, Na Acetate, Na2SO4 and MOPS to imitate 
conditions in relaxed conditions living muscle tissue. PEP and PK were added as part of the 
Regeneration system. RdATP, BSA and dATP were added for imaging purposes.  
 
Stopped Flow buffer 
25 mM KCl, 20 mM MOPS, 5 mM MgCl2, 1 mM Na-azide  
 
 
B. Muscle preparation  
i. Chemical skinning of rabbit psoas skeletal muscles  
Rabbit psoas skeletal muscles were dissected from tissues using the following skinning method. 
First, 3-4 cm long and 1-2 mm in diameter muscle fibres were dissected from flash-frozen psoas 
muscle. Second, they were tied to the toothpick with a strong thread by each end of the fibre, so 
the middle part of the fibre remained loose while the ends were fixed to the toothpick. Third, 
sample sticks were equilibrated in 25 ml of Fibre preparation buffer by adding 50 ml Fibre 
preparation buffer to the 50 ml tubes containing toothpicks with the sample; the sample was 
kept on ice during equilibration. Fibre preparation buffers were changed four times every 30 
minutes. Fourth, fibres were skinned for 2 hours by adding 50 ml Fibre skinning buffer to the 50 
ml tube containing sample sticks. Finally, sample sticks were equilibrated with 50 ml fibre storage 
buffer at 4°C for 2 hours before moving them to permanent storage at -20°C. 
ii. Myofibril preparation of skinned rabbit psoas skeletal muscles  
On the day of the experiment, a small part of the skinned skeletal muscle was cut for myofibril 
preparation. Skeletal muscle stick was placed into Wash buffer, and a piece of a muscle: 2-3 cm 
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long, 2-3 mm thick was cut from set muscle stick. The rest of the stick was placed back into a fibre 
storage buffer and stored for future use. All muscle cutting and dissections were performed on 
ice. A long piece of tissue cut from the stick was further cut into smaller pieces, each ~0.75-1 cm 
long. Smaller pieces were then stripped into smaller strips. It was found that smaller strips 
provided better myofibrils during imaging. It was also found that strips that were unbroken 
during stripping have also provided better images. Strips were then transferred into 800 ul 
Washing Buffer one by one to prevent them from sticking together and forming knots that would 
later decrease the quality of obtained images. Buffer containing strips were then homogenized 
(Tissue Ruptor II, Qiagen) twice using the following template: high speed for 20 sec followed by 
slow speed for 10 sec with a 30-sec break on ice in between. Homogeniser has moved around 
while homogenising to ensure complete homogenisation of the sample. The homogenised 
sample was then observed under the light microscope under max magnification (x400) for quality 
control purposes. Under a light microscope, myofibrils should appear long, thin-medium thick 
(~1 uM), striated filaments. Further quality control was established by measuring OD600 using a 
spectrophotometer. Measuring OD600 provided a rough estimate of the density of the myofibrils 
in the sample, thus allowing all experiments to have approximately the same myofibril density. 
Wash buffer was used as a blank for the spectrophotometer, and the optimal OD600 was found 
to be ~0.85 ±0.1.  
 
C. Preparation of flow cell chamber  
Flow cells are an assembly of standard microscope slides, gaskets, and coverslips. Microscope 
slides were modified by drilling two 3 mm diameter holes followed by shaking at 150 rpm on an 
SK-0180-Pro overnight in a 100 % ethanol bath. Gaskets were created from double-sided tape 
cut into 10x15 mm (inner dimensions) rectangles with a hollow centre. Coverslips were also 
cleaned in 100 % shaking (same conditions as above) ethanol bath overnight. To further ensure 
that slides and coverslips were clean, each was plasma cleaned (PDC-32G-2, Harrick Plasma) for 
5 minutes on the max setting. After coverslips were plasma cleaned, one of their sides was coated 
in 5 ul of 15 ug/ml poly-l-lysine. Another plasma cleaned coverslip was then used to spread poly-
l-lysine evenly on the surface of other coverslips. Poly-l-lysine covered coverslips were allowed 
30 min to dry before assembling the flow cell by attaching gasket atop the slide followed by the 
coverslip, poly-l-lysine covered side facing the slide. When combined with other parts of the flow 
cell gasket produced an enclosed 30ul space between the coverslip and the slide surface (see 






Representation of assembly of the flow cell. A 10 mm x 15 mm gasket is placed on the slide with holes (3 mm in 
diameter). The gasket is then covered by a coverslip creating ~30 ul space between the coverslip and the slide 
surface.  
 
D. Rigor conditions experiments 
i. Rigor conditions experiments without MAVA 
Following myofibril preparation in rigor conditions, 30 ul were taken from the prepared 
myofibrils sample and incubated with 30 ul 50 nM RdATP Imaging Buffer. 200 nM anti-alpha-
actinin (Monoclonal Anti-α-Actinin (Sarcomeric) antibody produced in mouse, A7811, Sigma) and 
200 nM Alexa 488 (Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 
488, A11001, ThermoFisher) were both diluted in 30ul Wash buffer and also added to the sample. 
This sample was allowed to incubate for 2 h on ice and wrapped in tin foil for fluorophore 
preservation. 50nM RdATP in imaging buffer containing an ATP regeneration system (described 
below) enabled any ADP molecules to be converted into ATP over 30 mins. The regeneration 
system was also added to the 250 uM dATP Wash Buffer to maintain the regeneration process 
after the final wash. After a 2 h incubation, sufficient fluorescently labelled ATP was exchanged 
onto the myosin heads such that 1 in 1e6 molecules was labelled. A further 30 min incubation 
followed the introduction of the myofibrils into the flowcell to permit attachment to the poly-l-
lysine coated coverslip. Following the 30 min incubation, 100 ul of 250 uM dATP Wash Buffer 
(final wash) was flowed into the flow cell to remove the excess RdATP, thus decreasing the 
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background noise during imaging. Imaging the first myofibril was started <2 min after the 250 
uM dATP Wash Buffer was introduced. 
ii. Rigor conditions experiments with MAVA 
Mavacamten was diluted in 100 % DMSO to 3uM and added to 250 uM dATP wash buffer. 
Previous investigations (Mariano et al., 2001) show DMSO may have an inhibitory effect on 
contractile proteins above 5 %; therefore, the concentration of DMSO to which the myofibrils 
were exposed was kept below 5 % at all times. 
 
 
E. Relaxed conditions experiments 
i. Muscle preparation conditions  
Prior to the rigor approach, the relaxed approach was used. In this approach, relaxed (5 mM 
dATP) conditions were maintained throughout myofibril preparation and throughout all flow cell 
setup steps except for the last one. During the last step, dATP concentration varied depending 
on desired fATP/dATP ratio but was never dropped low enough to drive myofibrils into the rigor 
state.  
ii. Flow chamber setup for imaging  
Flow cell preparation in relaxed conditions was done very differently from rigor preparation. 
During the following explanation, Washing Buffer (relaxed) was made with different dATP 
concentrations that depended on the RdATP/dATP ratio used for different experiments. First, the 
flow cell was washed with 3x100 ul washing buffer relaxed followed by 30 min incubation. While 
the flow cell was incubating, Alexa-488 (200 nM) and anti-alpha-actinin (200 nM) were 
conjugated and left to incubate for 1 h. Second, freshly prepared myofibrils (30 ul) in relaxed 
conditions were flown into the flow cell and further incubated for 30 min. Following 30 min 
incubation period, excess myofibrils were washed away with 100 ul wash buffer relaxed. BSA 
(100 ul,10 mg/ml) was then flown in and left to incubate for 2 min to be swiftly removed by 100 
ul wash buffer relaxed. Conjugated Alexa 488 and anti-alpha-actinin were diluted in 30 ul washing 
buffer relaxed and flown into the flow cell. The flow cell was incubated for 1 h with additional 
coverage for photobleaching protection. There was some variation for the next step depending 
on the RdATP/dATP ratio. If RdATP/dATP ratio provided too much background noise during 
imaging an additional 100 ul wash buffer, the relaxed wash was introduced to reduce set 
background noise. However, if the background did not interfere with obtaining attachment 
reading, the last 100 ul wash was not applied. In Mavacamten experiments, mavacamten was 
introduced either with final 100 ul wash or second-to-last wash, again, depending on the 
background and RdATP/dATP ratio. Mavacamten had the same 3 uM concentration, 1.5 %DMSO 
and was incubated for 10 min.  
F. Stopped flow experiments 
The stopped-flow spectrometer used throughout this thesis was an SF-61 DX2 
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manufactured by HiTech Scientific, which was capable of double mixing but only used for single 
mixing. The stopped-flow contained two 700 µL sample syringes driven by air pressure from an 
external air pressure pump. Both syringes were triggered simultaneously, pushing the reactants 
into an observation cell in the optical light path of a high-intensity light source. The light source 
used for these experiments was a LED lamp (290 nm) (ocean optics). The fluorescence of the 
sample was detected via a photomultiplier placed at a right-angle to the incoming light. When 
the samples reached the observation cell, they were mixed in a 1:1 ratio resulting in the 
concentration of both reactants being halved. As the solution left the observation cell, it filled 
the empty stop syringe, forcing the syringe to hit a back-stop, which immediately ceased the flow. 
The samples syringes were temperature controlled by an external water bath. 
 
i. RdATP experiments [ATP/ADP] 
To determine if Rhodamine labelled ATP we have used contained acceptable ATP/ADP ratio 
following stopped-flow experiment was conducted. Myosin head sub-fragment 1 (S1) was mixed 
with Rhodamine ATP. S1 concentration was decreased throughout the experiment from 2.5 uM 
to 39 nM while RdATP concertation was kept constant at 1 uM. Similarly, S1 was mixed with 
RdATP that was mixed with regeneration system (PEP/PK). Data obtained from two experiments 
were then compared to determine if the regeneration system in pace was working. This 
regeneration system will be described in further detail in the next section of this thesis. All 
concentrations stated in this section are pre-mixing concentrations. 320 nm filter was used for 
both experiments. A stopped Flow buffer was used for both experiments. 
G. ATP Regeneration system 
ATP regeneration system was kept constant throughout all experiments. ATP was regenerated 
using a mixture of pyruvate kinase (PK) and lactate dehydrogenase enzymes as well as 
phosphoenol pyruvate (PEP), which had provided inorganic phosphate (Pi) to convert ADP into 
ATP (see Figure 16). The PEP concentration for the regeneration process was kept at the same 
concertation as the RdATP concertation to ensure the excess of Pi in the solution. 1 ul of PK was 
added to each reaction. All reagents (PEP, PK and RdATP) were mixed and allowed to incubate 
for 30 min. The process of incubation was introduced to allow ample time for RdADP to 
regenerate into RdATP. Following the incubation, dATP was added to the mixture. dATP 
concentration was adjusted according to desired RdATP/dATP concentration ratio. All dilutions 





A schematic reaction of what occurs during the ATP regeneration process. PEP is broken down into pyruvate and 
inorganic phosphate. Pi is released and can be taken up by ADP to create ATP. PK catalyses this transfer of Pi. ATP is 
then broken down into ADP with a release of energy, and the process is repeated until no PEP is left.  
 
8. Results  
Before we began our imaging and consequent analysis, a simple question was asked. How much 
of our RdATP stock is ATP, and how much has deteriorated into ADP? Stopped flow experiments 
were created to determine the exact concentration of ATP in our RdATP stock solution. Once the 
first experiment was conducted, and it was established that our RdATP mainly was consistent 
with ADP (>50 %), the Regeneration system was introduced to increase ATP concentration. 
Stopped flow analysis was then conducted on Regenerated RdATP to confirm the increase in ATP 
concentration. To determine the spatial arrangement of myosin heads in each zone of thick 
filament and compare SRX and DRX states from obtained videos, we have utilised the TrackMate 
plugin of ImageJ and a series of excel spreadsheets. Trackmate was used to track fluorescent ATP 
attachments to different zones, and Alexa488 labelled anti-alpha-actinin attachments to Z-lines. 
X and Y coordinates, as well as the duration of each track, were recorded. The data from 
TrackMate was then transferred into a series of spreadsheets that would place each track in 
different zones of the sarcomere, thus producing each sarcomere is a list of tracks for each zone 
in the thick filament. Data from each zone would be then fitted to three exponentials, 
representing three different states of myosin heads, to determine the proportions of each state 





A. Data Analysis 
i. Stopped flow analysis 
Data collected from stopped-flow experiments were analysed using the following method. The 
fluorescent measurements collected during experiments were plotted against S1 concentrations 
for both Regenerated and non-regenerated RdATP samples (see Figure 16). Fluorescent emission 
was measured for tryptophan(ATP Binding and Hydrolysis by MX-S1 in the Absence of Actin. A,... 
| Download Scientific Diagram, n.d.) on S1 (ex=290 nm, em=340 nm) that was bound to RdATP 
but not for Rhodamine fluorophore (ex=570 nm, em=590 nm). The fluorescence of Rhodamine 
was cut out by using a 320 filter. Fluorescents produced by tryptophan would increase with the 
increase of RdATP+S1 complexes. As RdATP concentration was kept constant at 1 uM throughout 
the experiments while S1 concentration was changed, the fluorescent reading would increase 
with the increase of S1 concentration until all S1 molecules would be coupled in RdATP+S1 
complexes. At this point, the fluorescent intensity would reach the maximum value (Amax) and 
plateau. It must be said that the concentrations that are stated above are pre-mixing 
concentrations; thus, although the Amax would be observed at S1 concentration ~1 uM, the 
actual concentrations of S1 and RdATP inside the mixing chamber at this moment will be halved 
(~500 nM at 100% ATP). The actual RdATP concentration was derived from the Michaelis-Menten 
plot (see Figure 17). From Michaelis-Menten equation Km=½ Vmax or Km=½ Amax in this case, where 
½ Amax is half of the maximum amplitude change for each fit. Comparing Km of each plot to the 
theoretical [RdATP] at ½ Amax indicated the contamination of RdATP with RdADP. The analysis 
indicated that more than 90% purity was achieved with the regeneration system, while the 
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Figure 17. 
An output of OriginPro (“Origin 2022 Feature Highlights” n.d.) including a graph and two tables with Km and Vmax 
values specific to an S1 ATPase affinity for RdATP calculated from stopped-flow experiments. 
A) A graph plotted to compare Unregenerated and Refined RdATP. Black dots correspond to experimental data with 
the ATP regenerating system, whereas red dots correspond to experiments without such a system.  Both data sets 
were fitted to Michaelis-Menten equations (see Figure 17 B and C). The black and red lines correspond to refined 
and unrefined RdATP data, respectively. B) A table showing OriginPro output for unrefined data. C) A table showing 







ii. Image acquisition using OAF microscopy and microscope setup  
All experiments involving flow cells were conducted using custom-built oblique angle fluorescent 
(OAF) microscope, described here (Desai et al., 2015). Rhodamine ATP was excited using a 561 
nm diode OBIS LS laser (coherent, USA) at 20 mW, and Alexa-488 labelled antibodies were excited 
using Oxxius 488 nm also at 20 mW. All images were acquired using the OrcaFlash 4.2 camera 
(Hamamatsu, pixel size 63.2 nm) using 1x1 binning. Flow cells were placed on a microscope stage 
and fixated. Brightfield camera (Swann, C500 CCD Colour Camera) was then used to establish an 
approximate focus of appropriate (see 8.B.ii) myofibril. Imaging was then switched from 
brightfield to fluorescent (OrcaFlash 4.2), and a 488 nm laser was switched on. Images were 
displayed in the live feed using ImageJ. During video acquisitions, the 488 nm laser was turned 
on initially to establish a clear focus without risking photobleaching of the RdATP. Images of 
Alexa-488 labelled Z-lines were acquired for the first 30 seconds, after which the 488 lasers was 
switched off, and 561 lasers were switched on to image ATP attachment (see Figure 18). The laser 
ON time was 200 ms during stroboscopic imaging, including laser pre-exposure time (10 ms). 
These two parameters were kept constant throughout all experiments while laser OFF times was 
changed depending on the desired time frame (i.e. overall time 5 s,2 s,1 s etc.). Stroboscopic 
illumination was set using a custom-written program (Arduino). Once imaging of a single 
myofibril was done, the microscope was switched to brightfield again to find a new myofibril for 












Figure 18.  
Images were collected using ImageJ, Orca and lasers described above during stroboscopic illumination with a time 
frame of 5 sec in MAVA- conditions.  
A) Shows the image that was collected during 488 lasers ON time. Alexa488 bound to alpha-actinin is visible, thus 
marking all z-lines of the selected myofibril. The red oval represents one of many z-lines present in this image.  
B) A period of imaging once the 488 lasers were switched OFF and 561 lasers were switched ON. Some rhodamine 
ATP attachments are visible and labelled with red circles.  





iii. Single-molecule fluorescent microscopy  
1. TrackMate settings and analysis  
TrackMate analysis was divided into two parts. During the first part, only Alexa488 fluorophores 
were tracked as only 488 nm laser was on, and thus only z-line were illuminated. 488 nm laser 
was switched off after 30 seconds of illumination, and 561 nm laser was switched on for the rest 
of the acquisition. Only RdATP fluorescence was analysed during the second part as 561 nm laser 
excites Rhodamine but does not excite Alexa488. The 488 nm illuminated part of the video will 
be referred to as the first part of the video, and the 561 nm illuminated part of the video will be 
referred to as the second part of the video. A z-line stack (max intensity) of horizontal slices was 
made for each second part of the video to ensure that all tracks were correctly recorded. In some 
cases, tracking was interrupted due to the fluorophore being too dim or moving too far away 
from the initial binding. With the z-line stack, this problem was eliminated as clear lines of RdATP 
attachments were visible with a naked eye (see Figure 19).  The first part of the video was loaded 
onto the ImageJ, and the TrackMate plugin was loaded. The video properties were altered to 
represent the microscope setup (i.e. the number of frames, pixel characteristics and frame 
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interval). LoG detector was then used with an estimated fATP attachment diameter of 390 nm. 
The threshold was established through trial and error to only labelled z-lines excluding other 
random fluorescence. Following the detection, HyperStack Displayer was chosen for view 
representation. No additional filters were established during any steps of TrackMate analysis. A 
simple LAP Tracker was chosen to track the fATP attachment. Both Linking max distance and Gap-
closing max distance were set to 100 nm, while the Gap-closing max frame gap was set to 20 
frames. Some variation in Gap-closing max frame gap was allowed to ensure the entire length of 
attachments were recognised as a single attachment. Data was then extracted in two excel 
spreadsheets showing X and Y positions of each track and the duration of each track. Analysis 










The following images show the process TrackMate analysis of a single stroboscopic 5 s video as an example 
of set analysis. Only ATP attachments are shown here, but Z-lines were analysed using the same principal 
The first image shows the determination of the threshold and fATP attachment diameter. Although fATP 
attachment diameter was not changed throughout all analyses, the threshold changed each video. Purple 
circles represent tracks on that frame that TrackMate is going to follow. 
The second image shows the same frame and purple tracks but with all other frames added to this frame. 
These new tracks are represented in multicoloured dots. The dot's colour depends on how long this 
particular track has stayed on the myofibril before de-attaching.   
The last two images represent typical data that was obtained from each video. This data provided us with 
the exact x and y positions of each track and tracks duration.  
 
2. Correcting tilted z-lines and ATP position extraction for each sarcomere 
As stated above, at the end of the TrackMate analysis, we were left with each track's x and y 
positions and track durations. It was decided that ATP attachment data should be extracted from 
one sarcomere at the time so we could first recalculate each x-position into relative position 
between two z-lines (disused in more detail in next section) and then allocate each ATP track into 
C, D or P zones of the thick filament. As not all z-lines were perpendicular to the x-axis, it was 
vital that we devised a method to make them so and at the same time correct ATP positions in a 
way that would move them together with corrected z-lines. The tilted z-lines correction was done 
due to the following argument. If z-lines were corrected, we would be able to pick up all ATP 
tracks between them using the x position of Z-lines at each end of the sarcomere and search the 
spreadsheet for ATP tracks that had x-values between two z-line x-values. If we were to proceed 
with z-lines analysis in tilted positions, we would not be able to extract ATP tracks in a way that 
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utilises x coordinates of Z-lines as we would be excluding or adding some ATP tracks that would 
otherwise lay within other sarcomeres.  With this argument in mind following method was used 
to correct tilted z-lines. Data obtained from TrackMate analysis was transferred into the excel 
spreadsheet where both ATP and z-line positions were plotted. The x coordinates of the 
beginning and the end of one z-line were used to search all z-line tracks that lay between these 
two coordinates, essentially selecting only the z-line tracks that make up singular z-line. The tilt 
was corrected by fitting the Z-line to the left of the sarcomere and then correcting all of the 
positional data to that fit. The same was then applied to ATP positions (see Figure 20). This 










Figure 20.  
A graphical representation before and after tilted Z-line correction for a single relaxed, stroboscopic (5 sec) video. 
These graphs show that although the z line was tilled at the top graph (a bit to the left),  it appears to be straight on 
the second graph. Z-lines are represented by blue dots, while red dots represent RdATP attachments. Circled (yellow 
circles), red or blue dots represent the dots that are currently being corrected. Scales on both graphs are a 
representation of x and y coordinates of dots and should be disregarded.  
 
3. Relative ATP positions in sarcomere  
The next difficulty that presented itself after the tilted z-lines fix was that all sarcomeres had 
different lengths, and thus the plan of overlaying them to create a meaningful pattern was 
impossible. Myofibrils and, consequently, sarcomeres differ in sizes naturally, which was 
observed throughout our experiments. If we overlay sarcomere with a more considerable 
distance between Z-lines and sarcomere with a smaller distance between Z-line, obtained, data 
would be inaccurate. Thus, the solution was devised to overcome this problem. The solution was 
to create a relative position of ATP x coordinated. We have judged that even though the length 
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throughout sarcomeres. For that reason, we have calculated the mean position of each z-line (in 
the x-axis) to then use (a+b)/c, where a is the mean position of the first z-line, b is the ATP 
coordinate on the x-axis, and c is the mean position of the second z-line. With his formulae, x 
positions of ATP were corrected to become relative to the whole length of the sarcomere while 
ignoring the actual length making it possible to overlay all sarcomeres with ease. Relative 
positions were then binned using C, D and P zones of the thick filament as bins to accurately 
represent attachment frequency for the whole myofibril neatly overlayed in one graph.  
 
4. Determining the ratio of myosin heads states with regards to different zones  
After relative ATP positions were established, thus providing us with both frequency and the 
duration for each zone, durations of set tracks were taken and plotted onto separate graphs, 
each representing a different zone. All graphs were set to a logarithmic scale to better represent 
data fitted to two-three exponentials depending on which experimental data was represented. 
Relaxed experiments were best fitted by three exponentials, while two exponentials better 
represented newer rigor experiments. Rigor method of experimentation was established very 
close to the end of this project and thus did not have ample time to be developed into a working 
condition; thus, data from these experiments will not be presented in this thesis. The fitting was 
done by an inbuilt tool in excel - “solver”, thus rendering human error to a minimum. Relative 
ratios of myosin heads states were calculated using amplitudes and rate constants provided by 
fitting three/two exponentials. Amplitudes that were derived from exponentials were corrected 
in relation to each other. A correction was necessary as all states have different rates. States with 
slower rates will show smaller amplitudes during the analysis than states with faster rates. The 
slower state will process fewer ATP molecules than faster states in the same amount of time; 
thus, the correction must be made to equilibrate the difference in ATP molecules to better 
represent the actual state's ratio. The correction was done using a simple equation, (kB/ 
kA)*ampA = ampcorrA, where kB is the rate constant of DRX, kA is the rate constant for SRX, 
ampA is the uncorrected amplitude for SRX, and ampcorrA is the corrected amplitude for SRX. 
SRX rate constant and uncorrected amplitude in this equation was then swapped with active 
state rate constant and uncorrected amplitude to determine corrected amplitude for the active 
state. These calculations related SRX and active state to DRX; thus, DRX uncorrected amplitude 
and DRX corrected amplitude had the same value. It must be said that although it was chosen to 
relate all states to DRX, it could have been any other states with the same result. Finally, the 
relative percentage of myosin heads for each state was calculated. It was done by dividing each 
corrected amplitude by the sum of all amplitudes (e.g. ampcorrSRX / (ampcorrDRX + 
ampcorrActive + ampcorrSRX) = rel% SRX, where ampcorrSRX is the corrected amplitude for SRX, 
ampcorrDRX is the corrected amplitude for DRX, ampcorrActive is the corrected amplitude for 
active state and rel% is the relative percentage of heads in SRX state). 
 
 
B. Relaxed State experiments  
Experiments that were done for this thesis can be divided into two categories: relaxed state 
experiments and rigor state experiments. Although rigor experiments had given us better 
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preliminary outcome, we were not able to do an appropriate number of biological repeats to say 
with any confidence that data from rigor experiments can be used in this thesis without further 
work. On the other hand, relaxed state experiments were conducted in amplitude, and thus this 
data will be presented in full. Relaxed state experiments were conducted with and without MAVA 
for both 2000 ms and 5000 ms intervals. RdATP was regenerated using the regeneration protocol 
provided above, and RdATP/dATP concentration was kept at 5 nM/5 mM throughout all 
experiments. The following graphs (see Figures 21-24) represent different zones of the thick 
filament. From Figure 21-22, we have observed that with the introduction of MAVA to the 
system, all zones have a decrease in SRX states. The experiments were done in consequent 
succession as follows: 2 sec, 2 sec + MAVA, 5 sec, 5 sec + MAVA using the same tissues and 
reagents as well as flow cells that were prepared in the same batch. Data from 2-sec experiments 
had to lead us to conclude that although these experiments were done in three biological 
repeats, they will have to be regarded as anomalous, as the addition of MAVA was shown to 
increase SRX %, the effect that we have not observed here (in fact, the opposite is was observed). 
5-sec experiments (Figure 23-24) had much more expected results than 2-sec experiments. 
Experiments without MAVA have shown a clear distinction in relative SRX% between C-zone and 
D- and P- zones, where C-zone had a much larger relative SRX % than the other two zones. 
Comparing experiments with and without MAVA had shown an increase in relative SRX % in D 










Figure 21.  
Represents experiments done in 2 sec stroboscopic illumination, no MAVA conditions. In the above graphs, the 
active state is represented by a grey line, DRX with green and SRX with dark blue. The orange curve represents the 
sum of these three lines and thus the sum for rates and amplitudes of all three exponentials. Blues dots represent 
ATP duration attachments that were binned in 10 sec bins. Data presented here comes from three separate 
experiments (n=3). The relative ratio of myosin heads states for each zone was calculated to be:  
C-zone SRX - 10 %, DRX - 47 %, Active – 43 %  
D-zone SRX - 23 %, DRX - 52 %, Active – 25 %  































   
 
 
Figure 22.  
Represents experiments done in 2 sec stroboscopic illumination, with the addition of MAVA. In the above graphs, 
the active state is represented by a grey line, DRX with green and SRX with dark blue. The orange curve represents 
the sum of these three lines and thus the sum for rates and amplitudes of all three exponentials. Blues dots represent 
ATP duration attachments that were binned in 10 sec bins. Data presented here comes from three separate 
experiments (n=3). The relative ratio of myosin heads states for each zone was calculated to be:  
C-zone SRX - 10 %, DRX - 53 %, Active – 37 %  
D-zone SRX - 6 %, DRX - 51 %, Active – 43 %  































Represents experiments done in 5 sec stroboscopic illumination, no MAVA conditions. In the above graphs, the 
active state is represented by a grey line, DRX with green and SRX with dark blue. The orange curve represents the 
sum of these three lines and thus the sum for rates and amplitudes of all three exponentials. Blues dots represent 
ATP duration attachments that were binned in 10 sec bins. Data presented here comes from three separate 
experiments (n=3). The relative ratio of myosin heads states for each zone was calculated to be:  
C-zone SRX - 50 %, DRX - 38 %, Active – 12 %  
D-zone SRX - 13 %, DRX - 68 %, Active – 19 %  
































Represents experiments done in 5 sec stroboscopic illumination, no MAVA conditions. In the above graphs, the 
active state is represented by a grey line, DRX with green and SRX with dark blue. The orange curve represents the 
sum of these three lines and thus the sum for rates and amplitudes of all three exponentials. Blues dots represent 
ATP duration attachments that were binned in 10 sec bins. Data presented here comes from three separate 
experiments (n=3). The relative ratio of myosin heads states for each zone was calculated to be:  
C-zone SRX - 52 %, DRX - 41 %, Active – 7 %  
D-zone SRX - 30 %, DRX - 64 %, Active – 6 %  





Before discussing the results and advantages of our methods, we would like to present a 
mathematical model, which calculates a theoretical approximation of the percentage of SRX 
heads in a thick filament.  
A. Theoretical probability calculations 
Here we would like to propose a statistical construct to calculate an approximate number of 
fluorescently labelled ATP molecules that would bind to myosin heads with regards to 
fluorescently labelled ATP concentration, dATP concentration, the theoretical number of thick 
filaments in a sarcomere, the centre-to-centre distance between thick filaments, myofibril 
diameter and the number of myosin heads on the thick filament. As stated above, all relaxed 
experiments were conducted with 5 nM RdATP/5 mM dATP. According to the literature, the 
centre-to-centre distance between thick filaments was calculated to be ~43 nm(Millman, 1998). 
Also, according to other literature, rotational symmetry for the thick filament was shown to be 



























Furthermore, the same literature indicated that the diameter of myofibril could vary between 1-
2 um while the whole length of the thick filament was shown to be ~1600 nm(Al-Khayat, 2013). 
With these values, established calculations can now be made to estimate the statistical 
probability of observing the fluorescent event.  
The total number of thick filaments in one sarcomere was estimated by dividing myofibril 
diameter by centre-to-centre distance between thick filaments. The highest possible values were 
taken for the estimates to determine the largest possible outcome for the whole statistical 
analysis. 2000 nm/43 nm=46. There were 20-30 sarcomeres in each myofibril, so with that in 
mind multiplying the number of thick filaments for a sarcomere by the number of sarcomeres 
would provide us with the total number of thick filaments in the myofibril. 46*30=1380. The total 
number of myosin heads per thick filament was then established by dividing an approximate 
length of the thick filament by spacing of myosin heads repeat sequence and multiplying 
produced values by the number of myosin heads that were present in this sequence. 
1600/42.9*9=335. Now that we had both the total number of myosin heads per tick filament and 
the total number of tick filaments per myofibril, we were able to calculate the total number of 
myosin heads in myofibril by multiplying two values together. 335*1 380=462 300. To make it 
easier to count, let us round it up to 500 000. Statistical analysis of 500 000 myosin heads in one 
myofibril then continued using imaging buffer concentrations. 5 nM RdATP/5 mM dATP 
essentially states that for every 1 RdATP molecule, there are 1 000 000 dATP molecules present 
in the imaging buffer; thus, the chances of RdATP molecule binding to a myosin head instead of 
dATP molecule are 1e10-4 %. As we have calculated the approximate number of myosin heads in 
myofibril to be ~500 000, multiplication of these two values would produce the chances of one 
RdATP molecule to be seen on the image. 500 000 * (1e10-4) = 50 %. The probability of seeing a 
single RdATP at any particular point in time of the imaging process is 50 %. This value is a gross 
overestimation as we also must consider the fact that not all myosin heads are available for 
attachments at all times. Some of them might be undergoing SRX with dATP molecules attached 
and thus would be incapable of receiving RdATP. The same case can be made for DRX and active 
attachments. It is must also be remembered that we have taken the highest possible estimations 
for all values in previous calculations. Even then, this RdATP molecule that has attached to one 
myosin head has only 40 - 50 % (Stewart et al., 2010a;(Anderson et al., 2018)of being in SRX. 
0.5*0.5=0.25. There is only a 25 % chance that the RdATP molecule will attach to a single myosin 
head that is in SRX. If we were to say that we are considering only 50 % of myosin heads to be 
the inactive state and thus only 50 % are available for potential attachment of RdATP molecule 
per frame, then the chance of RdATP attachment to SRX drops to 12.5 %. Results from 5-sec 
experiments concur with that mathematical model and places overall myosin heads SRX % at 
11%. Please note that this percentage was calculated using uncorrected amplitudes as the 
mathematical model did not consider relative ATP turnover rates of different states.   
 
B. The spatial arrangement of SRX in all zones of the thick filament  
Analysis of our data had shown that myosin heads in SRX are largely located in the C-zone of the 
thick filament. Some SRX is present in both P and D zones but in much smaller quantities. This is 
consistent with some recent experiments (Nelson et al., 2020). Our values from 5-sec 
experiments can partially concur with work done by other groups where the population of SRX 
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in C, D and P zones without MAVA was found to be 61+-12 %, 9+-12 % and 13+-8 %, respectively, 
which fits our results. However, some variations with the same group concerning data acquired 
during an experiment with the addition of MAVA. Both our and Nelson et al. data have shown an 
increase in SRX % in P and D zones. Our increase (P-zone 11 %, D-zone 17 %), however, was not 
as large in comparison to Nelson el al (P-zone 42 %, D-zone 48 %). From this pattern of the spatial 
arrangement of SRX, a question may be asked: why C-zone has the largest SRX concentration? 
Myosin binding protein-C was connected (Li et al., 2019) with modulation myosin heads into SRX 
state. It can only be found in the C-zone of the thick filament. Mutations in a coding gene of 
MyBP-C were shown (see 6.C.) to cause SRX-related diseases. Striated muscle was only recently 
reported to have SRX (McNamara et al. 2014), and thus much information is still under debate 
about all aspects involving SRX of myosin heads. For example, the difference between isoforms 
of muscle tissue and SRX states associated with these isoforms were shown to have different 
reactions to activation (Hooijman, Stewart, and Cooke 2011). Are there any other differences 
between isoforms? Where does SRX appear in the sarcomere, and why there specifically? Do 
neighbouring myosin heads in SRX affect the states of adjacent heads? Some studies have shown 
that myosin heads interact and induce SRX in adjacent myosin heads if they are in SRX themselves 
in thick tarantula filament  (Woodhead et al. 2005) and later was shown to be the case in skeletal 
muscle (Brito et al. 2011; Sulbarán et al. 2013). Although we could not answer all of these 
questions, we aimed to determine the spatial arrangement of myosin heads in the A-band. Not 
many single-molecule studies were conducted in skeletal muscles, the most recent one being 
(Nelson et al. 2020), differences and similarities of which were discussed above.  
C. Advantages of our current methodology  
Although some of our experiments (2 sec) presented above provided us with some anomalous 
results, we are confident that other experiments (5 sec) have shown the advantages of our 
current methodology. First, our RdATP regeneration system has ensured that all attachments 
that we have observed can be attributed to RdATP, not RdADP attachments, as the regeneration 
system was present throughout interactions between RdATP molecules and myofibrils. Second, 
stroboscopic illumination has not only decreased the photobleaching effects of the lasers but 
have also provided us with the opportunity to calculate the rate of photobleaching. 
Unfortunately, not enough usable data was collected to implement set calculation, but it is a 
possibility for future experiments. Finally, keeping myofibrils in relaxed conditions throughout 
the experiment allows us to be certain that all myosin heads are not in rigor when images are 
taken.  
D. Future Projects 
Unfortunately, the time allocated for this project was not long enough to complete all goals put 
before us at the beginning of this project. First and foremost, this project was aimed to study 
cardiac muscle and mutations causing HCM. Thus, it is imperative for the future of this project to 
move from skeletal muscle onto cardiac and then, potentially, onto mutated cardiac muscle. To 
further develop our understanding of mechanics behind different states of activity in myosin 
heads and their connection to MyBP-C and its role in inducing SRX in myosin heads, we were 
planning to involve Protein Kinase A (PKA), which is thought to phosphorylate slow isoform of 
MyBP-C (Colson et al. 2012; Lim and Walsh 1986; Ackermann and Kontrogianni-Konstantopoulos 




10.  Conclusion 
A multitude of experiments has provided us with a working methodology of preparation for 
rabbit psoas skeletal myofibrils and consequent analysis. Set analysis has allowed us to determine 
the spatial arrangement of myosin heads in a super-relaxed state on the thick filament. However, 
although methods were established, much more work is required to produce more meaningful 
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